- Home
- MRSN vs PYPD Comparison
MRSN vs PYPD Comparison
Compare MRSN & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- PYPD
- Stock Information
- Founded
- MRSN 2001
- PYPD 2008
- Country
- MRSN United States
- PYPD Israel
- Employees
- MRSN N/A
- PYPD N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- PYPD Medical/Dental Instruments
- Sector
- MRSN Health Care
- PYPD Health Care
- Exchange
- MRSN Nasdaq
- PYPD Nasdaq
- Market Cap
- MRSN 40.7M
- PYPD 36.0M
- IPO Year
- MRSN 2017
- PYPD 2020
- Fundamental
- Price
- MRSN $0.29
- PYPD $3.50
- Analyst Decision
- MRSN Strong Buy
- PYPD Strong Buy
- Analyst Count
- MRSN 5
- PYPD 5
- Target Price
- MRSN $5.75
- PYPD $11.40
- AVG Volume (30 Days)
- MRSN 2.8M
- PYPD 1.4M
- Earning Date
- MRSN 08-12-2025
- PYPD 08-13-2025
- Dividend Yield
- MRSN N/A
- PYPD N/A
- EPS Growth
- MRSN N/A
- PYPD N/A
- EPS
- MRSN N/A
- PYPD N/A
- Revenue
- MRSN $34,006,000.00
- PYPD N/A
- Revenue This Year
- MRSN N/A
- PYPD N/A
- Revenue Next Year
- MRSN $1.30
- PYPD N/A
- P/E Ratio
- MRSN N/A
- PYPD N/A
- Revenue Growth
- MRSN N/A
- PYPD N/A
- 52 Week Low
- MRSN $0.26
- PYPD $2.30
- 52 Week High
- MRSN $2.83
- PYPD $4.42
- Technical
- Relative Strength Index (RSI)
- MRSN 38.23
- PYPD 56.01
- Support Level
- MRSN $0.27
- PYPD $3.42
- Resistance Level
- MRSN $0.36
- PYPD $3.62
- Average True Range (ATR)
- MRSN 0.03
- PYPD 0.18
- MACD
- MRSN -0.01
- PYPD -0.03
- Stochastic Oscillator
- MRSN 16.81
- PYPD 60.51
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.